Adalimab SC Injection 40 mg/0.8 ml contains Adalimumab, a biologic medicine used to treat several chronic inflammatory and autoimmune diseases. It belongs to a group of medicines known as tumor necrosis factor (TNF) inhibitors, which help reduce inflammation by blocking the action of TNF-alpha, a substance in the body that plays a major role in inflammatory processes.
Adalimab is administered as a subcutaneous (SC) injection, usually under the skin of the thigh or abdomen. It is widely used to treat conditions where the immune system mistakenly attacks the body’s own tissues. These include diseases such as Rheumatoid Arthritis, Psoriasis, and Crohn's Disease. By controlling inflammation, Adalimab helps relieve symptoms, prevent tissue damage, and improve overall quality of life for patients with these chronic conditions.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Each 0.8 ml prefilled syringe or injection contains:
Adalimumab 40 mg
Adalimumab is a recombinant human monoclonal antibody designed to target and neutralize tumor necrosis factor-alpha (TNF-α).
Biologic disease-modifying antirheumatic drug (DMARD)
TNF-alpha inhibitor
Immunomodulator
Adalimab SC Injection is indicated for the treatment of several inflammatory and autoimmune disorders, including:
Moderate to severe rheumatoid arthritis in adults.
Psoriatic arthritis, which affects joints and skin.
Ankylosing spondylitis, a chronic inflammatory disease of the spine.
Moderate to severe plaque psoriasis.
Crohn’s disease and ulcerative colitis, types of inflammatory bowel disease.
Juvenile idiopathic arthritis in children (under specialist supervision).
Hidradenitis suppurativa, a chronic skin condition causing painful lumps.
Doctors may prescribe Adalimab alone or in combination with other medications such as methotrexate to improve treatment effectiveness.
Adalimumab works by specifically targeting tumor necrosis factor-alpha (TNF-α), a cytokine that plays a central role in inflammation and immune system activity.
In many autoimmune diseases, TNF-α levels are abnormally high, which leads to excessive inflammation and tissue damage. Adalimumab binds to TNF-α and blocks its interaction with TNF receptors on cell surfaces. This prevents the inflammatory signaling pathway from continuing.
By inhibiting TNF-α, Adalimab helps:
Reduce inflammation and swelling
Decrease pain and stiffness in joints
Prevent structural joint damage
Improve physical function
Control immune-mediated tissue damage
This targeted action makes biologic therapies like adalimumab highly effective for chronic inflammatory diseases that do not respond well to conventional treatments.
Adalimab SC Injection should be administered under the supervision of a qualified healthcare professional.
Typical dosing guidelines include:
Adults: Usually 40 mg every two weeks as a subcutaneous injection.
Some conditions may require weekly injections depending on disease severity.
Injection sites include the thigh or abdomen, avoiding areas of skin irritation.
Patients may be trained to self-administer the injection after proper instruction.
Like other biologic medicines, Adalimab may cause side effects. Common ones include:
Injection site reactions (redness, swelling, or pain)
Headache
Upper respiratory infections
Rash
Nausea
Serious but less common side effects include increased risk of infections, tuberculosis reactivation, and allergic reactions.
রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন
Before starting Adalimab therapy, patients should consider the following precautions:
Screening for Tuberculosis is recommended.
Avoid use in patients with severe infections.
Caution in individuals with heart failure or immune disorders.
Vaccinations should be updated before starting treatment, but live vaccines should be avoided during therapy.
Regular medical monitoring is important during treatment.
Store in a refrigerator (2–8°C).
Do not freeze.
Keep the injection in its original package to protect from light.
Keep out of reach of children.
Login Or Registerto submit your questions to seller
No none asked to seller yet